Active Ingredient History
Fosbretabulin is a microtubule destabilizing experimental drug, a type of vascular-targeting agent, a drug designed to damage the vasculature of cancer tumours causing central necrosis. It is a derivative of combretastatin. It is formulated as the salts fosbretabulin disodium and fosbretabulin tromethamine. Wikipedia
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Central Nervous System Neoplasms (Phase 1)
Choroidal Neovascularization (Phase 2)
Drugs, Investigational (Phase 2)
Everolimus (Phase 1)
Fallopian Tube Neoplasms (Phase 2)
Hamartoma (Phase 2)
Head and Neck Neoplasms (Phase 2)
Livedoid Vasculopathy (Phase 2)
Macular Degeneration (Phase 1/Phase 2)
Myopia, Degenerative (Phase 2)
Neoplasms (Phase 2)
Neuroendocrine Tumors (Phase 2)
Ovarian Neoplasms (Phase 3)
Thyroid Carcinoma, Anaplastic (Phase 3)
Wet Macular Degeneration (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue